Cancer researcher battling Semafore in court
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
Drug discovery
Articles
Biopharma fueling boom in refrigerated warehousing
In the past few years, a handful of cold storage facilities have sprouted locally by playing to Indianapolis' strengths
in warehousing and life sciences.
Lilly hopes Elanco unit becomes a cash cow
Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco’s productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.
Chao exit hurts drug development industry
Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
Harlan Labs names new CEO
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
Ariad loses $65M patent appeal against Eli Lilly
Monday’s decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly’s osteoporosis
drug Evista and sepsis medicine Xigris.
Lilly sues to block generic of Adcirca lung treatment
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
Lilly pays $50M-plus for rights to testosterone lotion
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
Lilly, Transition Therapeutics make diabetes deal
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
To attack costs, Lilly accelerates R&D
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper.
Teva gets European OK to sell generic of Lilly’s Evista
Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
Lilly looks to autoimmune drugs
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.
Lilly shares get boost from OK of rival’s drug
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.
Eli Lilly’s shares slip after it forecasts mixed profits in coming years
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
Lilly launching new venture capital fund
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
Lilly forecasts growth in earnings next year
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
Lilly extends research pact with India firm
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
Lilly stock droops after rival claims faster-acting impotence pill
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly’s Cialis.
Aarden Pharmaceuticals chose Indianapolis over San Diego for headquarters
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
Eli Lilly CEO banking on new drug pipeline
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.